This exploratory study aims to evaluate the diagnostic, prognostic and response predictive
value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine
Tumors (GEP NETs) originating from the midgut or pancreas. Using a recently developed
methodology enabling the evaluation of 92 concomitant cancer biomarkers will provide an
interesting approach to solve this question (Lundberg et al 2011).